<code id='D99E280C6C'></code><style id='D99E280C6C'></style>
    • <acronym id='D99E280C6C'></acronym>
      <center id='D99E280C6C'><center id='D99E280C6C'><tfoot id='D99E280C6C'></tfoot></center><abbr id='D99E280C6C'><dir id='D99E280C6C'><tfoot id='D99E280C6C'></tfoot><noframes id='D99E280C6C'>

    • <optgroup id='D99E280C6C'><strike id='D99E280C6C'><sup id='D99E280C6C'></sup></strike><code id='D99E280C6C'></code></optgroup>
        1. <b id='D99E280C6C'><label id='D99E280C6C'><select id='D99E280C6C'><dt id='D99E280C6C'><span id='D99E280C6C'></span></dt></select></label></b><u id='D99E280C6C'></u>
          <i id='D99E280C6C'><strike id='D99E280C6C'><tt id='D99E280C6C'><pre id='D99E280C6C'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          leisure time

          author:explore    - browse:67747
          Rachel Haurwitz of Caribou Biosciences
          Rachel Haurwitz, CEO of Caribou Biosciences. Elizabeth D. Herman for STAT

          Caribou Biosciences said Thursday that its off-the-shelf CAR-T therapy induced durable, complete remissions in patients with advanced B-cell lymphoma that move it closer to the benchmarks set by more established, patient-specific CAR-T therapies.

          In an update to an early-stage study, 44% of the 16 patients treated with Caribou’s on-demand therapy, called CB-010, achieved a complete remission lasting a minimum of six months — a key threshold of durability.

          advertisement

          The CB-010 result is still preliminary, but it begins to compare favorably to currently approved CAR-T therapies, which must be custom made for each patient and have shown durable remission rates in the range of 36-40%, said Caribou CEO Rachel Haurwitz.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          leisure time